Speculation over a return for Vioxx

Share this article:
The FDA's decision to allow Pfizer's Celebrex to remain on the market yesterday has led to speculation by some that Merck's Vioxx could also return, should the company seek its re-introduction.
A report published today on the business Web site Marketwatch.com said some investors are hoping Vioxx may make a comeback. In the report, Merck said it looked forward to discussions with the FDA over Vioxx but would not confirm whether negotiations with the agency had already begun.
During yesterday's briefing on marketing changes for non-steroidal anti-inflammatory drugs (NSAIDs), the FDA said it would "carefully review any proposal from Merck" for resuming the marketing of Vioxx and would likely discuss the review with the new FDA Drug Safety Oversight Board and an Advisory Committee before making a final decision.
In a statement yesterday, Merck added that while it respects the FDA's position on use of NSAIDs and cardiac trouble in some patients, it also believes there is still a patient need for the drugs.
Share this article:

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.